Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

Core Viewpoint - Y-mAbs Therapeutics, Inc. is set to report its fourth quarter and full year 2024 results on March 4, 2025, indicating ongoing developments in its biopharmaceutical operations focused on cancer treatment [1][2]. Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment [3]. - The company utilizes advanced technologies such as the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies from the Y-BiClone platform [3]. - Y-mAbs has a robust product pipeline, including DANYELZA® (naxitamab-gqgk), which is the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma in specific patient conditions [3]. Upcoming Events - A conference call and webcast will be held on March 4, 2025, at 8:00 a.m. ET to discuss the financial results, with a live audio webcast available on the company's Investor Relations website [2].